Dr. Lal PathLabs Limited (DLPL), a frontrunner in diagnostic healthcare, has launched a groundbreaking diagnostic test—Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry. With this introduction, DLPL becomes the first diagnostic chain in South Asia to offer this specialized test, setting a new benchmark in precision diagnostics.
Understanding Amyloidosis and the Need for Accurate Typing
Amyloidosis is a serious condition where misfolded amyloid proteins accumulate in vital organs, potentially leading to organ failure or even death. To date, scientists have identified over 40 types of amyloid proteins. Accurate typing is crucial, as treatment varies significantly based on the specific type. While the kidneys, heart, lungs, and skin are commonly affected, amyloidosis can target any organ in the body.
Key Features of the Amyloid Typing Test
Dr. Lal PathLabs’ latest offering brings significant clinical value.
Key features include:
- First-of-its-kind in South Asia: DLPL leads the way in advanced amyloidosis diagnostics
- Nationwide Accessibility: Hospitals and collection centers across India can send samples to DLPL’s National Reference Lab in Rohini, New Delhi
- Precise Diagnosis: The test enables accurate identification of amyloid subtypes, supporting personalized treatment decisions
- Hospital Integration: Medical facilities can easily collect and forward patient samples to DLPL for seamless testing
Leadership Perspectives on the Launch
Speaking about the launch, Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, emphasized the company’s commitment to world-class healthcare:
“Our mission is to deliver globally competitive diagnostics to every corner of India. By introducing this advanced amyloidosis test, we aim to empower doctors with crucial diagnostic insights.”
As per the press release, Dr. Alok Sharma, R&D Head and Director of Renal Pathology & Electron Microscopy, added:
“Accurate amyloid typing is vital for guiding treatment. This gold standard test, powered by Laser Capture Microdissection and Mass Spectrometry, allows precise identification of amyloid subtypes. It marks a significant step in bringing proteomics-based diagnostics to India.”
Backed by Global Expertise
Dr. Lal PathLabs developed and launched this test under the expert guidance of the National Amyloidosis Centre, London (UK), a global authority in amyloidosis research and care.
Reinforcing a Commitment to Advanced Diagnostics
This launch underscores DLPL’s continued drive to offer accessible, accurate, and advanced diagnostics across the country. By adopting cutting-edge technology and global best practices, Dr. Lal PathLabs continues to raise the bar for healthcare diagnostics in India.